Immunotope is a clinical stage biotechnology company specializing in the development of immunotherapy products for the treatment and prevention of cancer and chronic viral infections. Our innovative products work by activating the patient's own immune system to fight disease and prevent recurrence. We have a comprehensive approach to cancer therapy that focuses on the critical need to diagnose cancer at its earliest stages and develop effective treatments that can destroy tumors and prevent metastasis.

Our product portfolio includes treatments for ovarian, breast, prostate, lung, pancreatic, and colon cancer. At Immunotope, we utilize a platform that combines various technologies to achieve successful immunotherapy. We are dedicated to addressing the need for highly effective and curative treatments with minimal toxicity.

Additionally, we leverage the immune system's sensitive and specific nature to enable early detection of cancer. We also offer innovative tools and services for collaborative development of novel drug and diagnostic products. Our proprietary immunoproteomics technologies allow us to identify naturally processed and presented antigens associated with Major Histocompatibility Complex Class I and Class II molecules, which are exclusively present on diseased cells.

Immunotope has completed preclinical characterization studies and is currently preparing for a phase I clinical study in lung and pancreatic cancer. Join us in our mission to provide exceptional returns on investment to our shareholders while making significant contributions to the field of immunotherapy. For more information about our clinical and preclinical programs, science and technology, careers, business development, services, management and boards, news and media, please visit our website